These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2467015)

  • 21. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
    Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
    Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
    Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
    Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
    Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
    JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bawu decoction () ameliorates benign prostatic hyperplasia in rats.
    Eom JH; Cheon SY; Chung KS; Kim MD; An HJ
    Chin J Integr Med; 2017 Aug; 23(8):611-616. PubMed ID: 27838873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate.
    Hill M; Bílek R; Safarík L; Stárka L
    Physiol Res; 2000; 49 Suppl 1():S113-8. PubMed ID: 10984080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs.
    Vickery BH; McRae GI; Bonasch H
    Prostate; 1982; 3(2):123-30. PubMed ID: 6178098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nafarelin acetate and benign prostatic hyperplasia.
    N Engl J Med; 1988 Mar; 318(9):580-1. PubMed ID: 2448625
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
    Schlegel PN; Brendler CB
    Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
    Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
    J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
    Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
    Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer.
    Bertaglia V; Tucci M; Fiori C; Aroasio E; Poggio M; Buttigliero C; Grande S; Saini A; Porpiglia F; Berruti A
    Clin Genitourin Cancer; 2013 Sep; 11(3):325-330.e1. PubMed ID: 23531429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of telmisartan in the treatment of benign prostatic hyperplasia.
    Ishola IO; Anunobi CC; Tijani KH; Afolayan O; Udokwu VU
    Fundam Clin Pharmacol; 2017 Dec; 31(6):643-651. PubMed ID: 28727906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.